Viyash Scientific Ltd
Fri 22/05/2026,15:58:50 | NSE : VIYASH
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 248.80
Previous Close
₹ 247.54
Volume
3887387
Mkt Cap ( Rs. Cr)
₹10749.76
High
₹ 262.50
Low
₹ 244.62
52 Week High
₹ 268.70
52 Week Low
₹ 166.00
Book Value Per Share
₹ 20.48
Dividend Yield
0.00
Face Value
₹ 2.00
What’s Your Call?
Collective community sentiment on Viyash Scientific Ltd
Your Vote -
Buy
87.54%
Hold
6.28%
Sell
6.18%
87.54%
12640 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
246.06
5757
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
5757
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Viyash Scientific Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Viyash Scientific - Credit Rating- Others
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Credit Rating
-
Viyash Scientific - Analysts/Institutional Investor Meet/Con. Call Updates
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Viyash Scientific - Analysts/Institutional Investor Meet/Con. Call Updates
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Viyash Scientific - Copy of Newspaper Publication
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Viyash Scientific - Investor Presentation
-
Viyash Scientific - Press Release
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Viyash Scientific Q4 net profit zooms 746.57% at Rs 35.81 cr
-
Viyash Scientific - Board Meeting Outcome for Outcome Of Board Meeting
-
Viyash Scientific - Outcome of Board Meeting
-
Viyash Scientific - Outcome of Board Meeting
-
Viyash Scientific - Results For The Quarter And Year Ended 31 March 2026
-
Viyash Scientific - Demise
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Change in Management
-
Viyash Scientific - Analysts/Institutional Investor Meet/Con. Call Updates
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Viyash Scientific - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1) Of The SEBI (Listing Obli
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Credit Rating
-
Viyash Scientific - Credit Rating
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Viyash Scientific - General Updates
-
Viyash Scientific - Credit Rating
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Credit Rating
-
Viyash Scientific - Appointment
-
Viyash Scientific - Outcome of Board Meeting
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Change in Management
-
Viyash Scientific - Board Meeting Outcome for Outcome Of Board Meeting
-
Viyash Scientific has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Viyash Scientific - General Updates
-
Viyash Scientific - Change In Domain Name And Website Of The Company
-
Viyash Scientific - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Viyash Scientific - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Viyash Scientific - General Updates
-
Viyash Scientific - Updates
-
Viyash Scientific - Clarification Letter
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Resignation of Director
-
Viyash Scientific - Resignation
-
Viyash Scientific - Trading Window
-
Viyash Scientific - Shareholders meeting
-
Viyash Scientific - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Viyash Scientific - Report On Distribution Of Sale Proceeds Of Fractional Shares
-
Viyash Scientific - General Updates
-
Viyash Scientific - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Viyash Scientific - General Updates
-
Sequent Scientific
-
Sequent Scientific
-
Sequent Scientific signs agreement to buy Brazilian animal healthcare co
-
SeQuent Scientific
-
SeQuent announces launch of Citramox LA in EU
-
SeQuent announces launch of inhouse developed Halofusol in EU
-
Sequent Scientific signs agreement for acquisition of 40% stake in Provet
-
Sequent Scientific Ltd
-
SeQuent Scientific receives EIR from USFDA
Key fundamentals
Evaluate the intrinsic value of Viyash Scientific Ltd stock
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 3221.19 | 1187.034 | 1133.683 | 1077.461 | 1056.588 |
| Liabilities | 3221.19 | 1187.034 | 1133.683 | 1077.461 | 1056.588 |
| Equity | 87.37 | 50.06 | 49.886 | 49.887 | 49.674 |
| Gross Profit | 234.53 | -11.383 | -26.664 | -26.36 | -0.75 |
| Net Profit | 75.87 | 15.794 | 0.622 | -6.08 | 14.799 |
| Cash From Operating Activities | 119.12 | -1.125 | -26.944 | 37.746 | 9.364 |
| NPM(%) | 5.48 | 8.86 | 0.36 | -2.73 | 6.73 |
| Revenue | 1382.06 | 178.257 | 168.518 | 222.685 | 219.626 |
| Expenses | 1147.53 | 189.64 | 195.182 | 249.045 | 220.376 |
| ROE(%) | 8.48 | 1.76 | 0.06 | -0.67 | 1.65 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 08 Sep 2021 | 0.5 | 25 | 0 | 283.05 |
| 21 Aug 2019 | 0.2 | 10 | 0 | 68.05 |
| 20 Nov 2017 | 0.2 | 10 | 0 | 100.1 |
Peers
Other companies within the same industry or sector that are comparable to Viyash Scientific Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 705.80 | -0.07 | 0.00 | 140.40 | -26.19 | 0.71 |
| Lotus Eye Hospital and Institute Ltd | 109.19 | 1.26 | 352.23 | 511.59 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.00 | 0.14 | 0.00 | 3209.37 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 771.80 | 4.77 | 0.00 | 482.44 | -363.15 | 0.00 |
Company Info
2003 - Hon'ble High Court of Bombay approved the Scheme of Amalgamation of company with P I Drugs & Pharmaceuticals Ltd. 2007 -PI Drugs & Pharmaceuticals Ltd has informed that Dr. Gopakumar G Nair has joined the Board as Independent Director effective June 20, 2007. 2008 - PI Drugs Board recommends dividend @ 10% 2009 - PI Drugs & Pharmaceuticals Ltd equity shareholders approve Scheme of Amalgamation - PI Drugs & Pharmaceuticals Ltd Board recommends Dividend@ 10% - PI Drugs & Pharmaceuticals Ltd - Change of name of the Company from PI Drugs & Pharmaceuticals Ltd to Sequent Scientific Ltd. 2010 - SeQuent Scientific to invest Rs. 150 crore in three new therapeutic segments - Signs an MoU with Karnataka Government. 2011 - PI Drugs & Pharmaceuticals Ltd Appoined Mr. Vinayak Hegde as Company Secretary . 2012 - PI Drugs - Issue of Warrants on Preferential basis - PI Drugs - Alloted 10,00,000 fully paid equity shares of Rs. 10/- each --Registered Office of the Company has been shifted from No. 116, Vardhaman Industrial Complex, Lal Bahaddur Shastri Marg, Thane west - 400 601 to 301, 'Dosti Pinnacle', 3rd Floor, Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W) - 400 604. 2013 -Sequent receives US FDA Approval for ITS API Drug Manufacturing Facility at Mangalore. -Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint Venture to Create Leading Animal Health Company. 2014 -SeQuent Scientific Limited announces completion of Sale of Specialty Chemicals division to Songwon Industrial Group. -Sequent Scientific to acquire the business of Arvee Synthesis Acquisition to provide impetus to Human API business. -Sequent Scientific - Updates - Alivira completes acquisition of majority stake in Provet Veterinary Products AS, Turkey. 2015 -SeQuent Scientific to acquire Animal Health business of Lyka Exports -SeQuent Scientific inaugurates new Analytical Services Centre at Bengaluru 2016 - SeQuent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormone -Sequent Scientific commences production in Vizag facility 2017 -SeQuent Scientific said that , its arm Alivira has received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh. 2018 -SeQuent Scientific Limited (SeQuent), has said that its wholly owned subsidiary Alivira Animal Health Limited ("Alivira") through Alivira Ireland, has signed an agreement with simultaneous closing to acquire 100 per cent of Bremer Pharma, Zydus Cadila's Animal Health Business in Germany . 2020 -Sequent Scientific announces addition of new state-of-art Animal Health R&D Centre at Mumbai -SeQuent Scientific receives EIR from US FDA for its Analytical Laboratory at Bengaluru 2021 -Sequent Scientific forays into pet segment in Brazil -The company has said that Evance Saude Animal Health Ltda ('Evance'), Brazil, a subsidiary of the Company has entered into a definitive agreement for acquisition of 100% stake in Nourrie Sa£de e Nutri‡ao Animal Ltda ('Nourrie').\r\n\r\nIn this regard, -SeQuent Scientific Limited (SeQuent) has said that European Union Good Manufacturing Practices (EUGMP) approval of its tablets dosage manufacturing line in Turkey. -SeQuent received CEP approval for Diclazuril API2022-The Company BOD approved Acquisition of entire 100% stake in Tineta Pharma Private Limited.2024-The company Receives Prequalification Approval from World Health Organization for Albendazole API.2025-SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for TransformationalMerger.
2003 - Hon'ble High Court of Bombay approved the Scheme of Amalgamation of company with P I Drugs & Pharmaceuticals Ltd. 2007 -PI Drugs & Pharmaceuticals Ltd has informed that Dr. Gopakumar G Nair has joined the Board as Independent Director effective June 20, 2007. 2008 - PI Drugs Board recommends dividend @ 10% 2009 - PI Drugs & Pharmaceuticals Ltd equity shareholders approve Scheme of Amalgamation - PI Drugs & Pharmaceuticals Ltd Board recommends Dividend@ 10% - PI Drugs & Pharmaceuticals Ltd - Change of name of the Company from PI Drugs & Pharmaceuticals Ltd to Sequent Scientific Ltd. 2010 - SeQuent Scientific to invest Rs. 150 crore in three new therapeutic segments - Signs an MoU with Karnataka Government. 2011 - PI Drugs & Pharmaceuticals Ltd Appoined Mr. Vinayak Hegde as Company Secretary . 2012 - PI Drugs - Issue of Warrants on Preferential basis - PI Drugs - Alloted 10,00,000 fully paid equity shares of Rs. 10/- each --Registered Office of the Company has been shifted from No. 116, Vardhaman Industrial Complex, Lal Bahaddur Shastri Marg, Thane west - 400 601 to 301, 'Dosti Pinnacle', 3rd Floor, Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W) - 400 604. 2013 -Sequent receives US FDA Approval for ITS API Drug Manufacturing Facility at Mangalore. -Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint Venture to Create Leading Animal Health Company. 2014 -SeQuent Scientific Limited announces completion of Sale of Specialty Chemicals division to Songwon Industrial Group. -Sequent Scientific to acquire the business of Arvee Synthesis Acquisition to provide impetus to Human API business. -Sequent Scientific - Updates - Alivira completes acquisition of majority stake in Provet Veterinary Products AS, Turkey. 2015 -SeQuent Scientific to acquire Animal Health business of Lyka Exports -SeQuent Scientific inaugurates new Analytical Services Centre at Bengaluru 2016 - SeQuent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormone -Sequent Scientific commences production in Vizag facility 2017 -SeQuent Scientific said that , its arm Alivira has received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh. 2018 -SeQuent Scientific Limited (SeQuent), has said that its wholly owned subsidiary Alivira Animal Health Limited ("Alivira") through Alivira Ireland, has signed an agreement with simultaneous closing to acquire 100 per cent of Bremer Pharma, Zydus Cadila's Animal Health Business in Germany . 2020 -Sequent Scientific announces addition of new state-of-art Animal Health R&D Centre at Mumbai -SeQuent Scientific receives EIR from US FDA for its Analytical Laboratory at Bengaluru 2021 -Sequent Scientific forays into pet segment in Brazil -The company has said that Evance Saude Animal Health Ltda ('Evance'), Brazil, a subsidiary of the Company has entered into a definitive agreement for acquisition of 100% stake in Nourrie Sa£de e Nutri‡ao Animal Ltda ('Nourrie').\r\n\r\nIn this regard, -SeQuent Scientific Limited (SeQuent) has said that European Union Good Manufacturing Practices (EUGMP) approval of its tablets dosage manufacturing line in Turkey. -SeQuent received CEP approval for Diclazuril API2022-The Company BOD approved Acquisition of entire 100% stake in Tineta Pharma Private Limited.2024-The company Receives Prequalification Approval from World Health Organization for Albendazole API.2025-SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for TransformationalMerger.
Read More
Parent Organisation
Viyash Scientific Ltd.
Founded
28/06/1985
Managing Director
Mr.Rajaram Narayanan
NSE Symbol
VIYASHEQ
FAQ
The current price of Viyash Scientific Ltd is ₹ 246.06.
The 52-week high for Viyash Scientific Ltd is ₹ 262.50 and the 52-week low is ₹ 244.62.
The market capitalization of Viyash Scientific Ltd is currently ₹ 10749.76. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Viyash Scientific Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Viyash Scientific Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Viyash Scientific Ltd shares.
The CEO of Viyash Scientific Ltd is Mr.Rajaram Narayanan, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
